Altman Peter, President and CEO of BioCardia (BCDA), has filed 64 Form 4 transactions, all in a single company. The pattern is one-sided: he has spent $308,096.93 on open-market purchases and has not sold a single share. The only other activity is compensation-related, including $278,775.56 in grants and awards and a $67,711.44 tax withholding on July 2, 2026, which is automatic and not a discretionary sale.
The buying has been steady and recent. Since April 21, 2026, Altman has made 22 open-market purchases, with the largest single outlay being $5,550 on April 29. The pace picked up in July, with nine purchases that month, including two on July 8 for $5,335 and $5,208.30. The most recent filings show continued accumulation: $1,030 on September 29, $1,995 on September 23, and $872 on September 3. The individual amounts are small, ranging from $190 to $5,550, but the frequency is high.
Altman has not recorded a single open-market sale in the entire filing history. His total sell value is zero. The transaction stream is almost entirely purchases, with the only non-purchase items being the June 29 grant of $132,750, the July 6 award, and the July 2 tax withholding. The direction is unambiguous: a CEO who keeps adding small positions in his own company's stock, most recently in late September 2026, and has never sold.
AI-assisted summary